Login
20/20 Biolabs Inc logo

20/20 Biolabs Inc

2020gene.com

What Do They Do?

Develops and offers laboratory blood tests using artificial intelligence to screen for cancers and chronic diseases, serving consumers, employers and fire departments.

How Do They Make Money?

revenue
SegmentShareRevenue
BioCheck
7.4%
OneTest
88%
CLIAx
4.4%

Who Are Their Customers?

Consumers can order tests online and use at-home collection; fire departments, employers and physician practices are also customers, with pharmacy-based collection offered through a retail pilot.

Do Revenues Turn Into Profits?

No. It lost $3.7M in FY2025.

Operating income, FY2025
−163% of revenue
▼ −41% (Loss) vs FY2024 (−$5.7M, −324%)
Net income, FY2025
−183% of revenue
▼ −33% (Loss) vs FY2024 (−$5.6M, −317%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
▲ +37%
vs $535.1K in Q2 FY2025
Net income
▲ +79% (Loss)
vs −$840.9K in Q2 FY2025
OneTest share of revenue vs 88.4% in Q2 FY2025
  • Sep 3, 2026 Nasdaq notified the company of two listing-rule deficiencies It must address the bid-price requirement and submit a plan for the stockholders’ equity requirement.
  • Aug 17, 2026 Firefighter screening programs are expected to generate more than $1.0 million The company cited Vermont’s statewide initiative and Maryland fire department awards as sources of the expected revenue.
Revenue over time
BioCheck OneTest CLIAx
$2.5M$1.3M$0

Who Do They Compete With?

Competes with Grail, Thrive, and Exact Sciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support